CCR7 and acute lymphoblastic leukemia: However, since the mice survived on average more than 100 days after the final administration of the CCL198-83, it is unclear to what extent exposure of the T-ALL to a CCR7 function-blocking peptide that disrupts β2 integrin adhesion may affect the survival of the T-ALL cells within the animal.